AER-271

Research use only, not for human use.

AER-271 (AER271) is a selective, small molecule inhibitor of aquaporin-4 (AQP4), the prodrug of AER-270 with enhanced solubility.

AER-271 (AER271) is a selective, small molecule inhibitor of aquaporin-4 (AQP4), the prodrug of AER-270 with enhanced solubility; shows improved neurological outcome and reduced swelling in two models of CNS injury complicated by cerebral edema.Other Indication Phase 1 Clinical(In Vivo):AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest.AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5?mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke.

——

Animal Model:Male mice (C57BL/6J, 8-12?week-old, 25-30?g)Dosage:5?mg/kg Administration:Treated by i.p. injection Result:Had better outcomes with an average neurological score of 0.89±0.31 compared with control mice receiving vehicle had an average neurological score of 2.50±0.62.

AER271

Others

Other Targets

Other Targets

Other Indications

Other Disease

634913-39-6

463.653

C15H9ClF6NO5P

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (269.60 mM)

O=P(O)(OC1=CC=C(Cl)C=C1C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=O)O

2-{[3,5-Bis(trifluoromethyl) phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate

(-20℃)

With Ice Pack

≥ 2 years